SCHEMBL2891874

SCHEMBL2891874

CCC(=O)NCC(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22339735 0.95 MEN1 (0.46)
SCHEMBL7771322 0.80 CTSD (0.52)
SCHEMBL18515920 0.80 PSMB5 (0.46)
SCHEMBL7668119 0.77 MGAM (0.35)
SCHEMBL14590056 0.77 CA1 (0.41)
SCHEMBL6612599 0.77 FAAH (0.52)
SCHEMBL8533512 0.76 MEN1 (0.52)
SCHEMBL528195 0.76
SCHEMBL460909 0.76
SCHEMBL2651423 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5238909-A For preemergence or postemergence use EASTMAN KODAK COMPANY (US) 1993-08-24 US claimed
EP-0476760-A2 4-substituted isoxazole herbicides EASTMAN KODAK COMPANY (US) 1992-03-25 EP claimed
US-11786468-B2 Nanoparticles KING'S COLLEGE LONDON (GB) 2023-10-17 US disclosed
US-20230312648-A1 PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES YUYU PHARMA, INC. (KR) 2023-10-05 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
WO-2023057814-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS VINCERX PHARMA GMBH (DE) 2023-04-13 WO disclosed
US-20220119493-A1 IL-7R-ALPHA BINDING COMPOUNDS SAMSARA BIOCAPITAL, L.P. 2022-04-21 US disclosed
US-11203614-B2 Composite polypeptide having a metal binding motif and molecular construct comprising the same Immunwork Inc. (TW) 2021-12-21 US disclosed
EP-3903825-A1 BI-LIGAND DRUG CONJUGATE AND USE THEREOF Coherent Biopharma (Suzhou), Limited (CN) 2021-11-03 EP disclosed
US-20210052747-A1 SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF HANGZHOU DAC BIOTECH CO., LTD. (CN) 2021-02-25 US disclosed
US-20200291391-A1 CROSS-LINKED EPITOPES AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. 2020-09-17 US disclosed
CN-101328166-A 2-dihydroindole ketone derivate as protein kinase inhibitor and histone deacetylase inhibitor SHENZHEN CHIPSCREEN BIOSCIENCE (CN) 2008-12-24 CN disclosed
US-20080139597-A1 DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) 2008-06-12 US disclosed
WO-2007121920-A2 PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS NOVARTIS AG (CH) 2007-11-01 WO disclosed
US-20070149538-A1 Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors IRM LLC (BM) 2007-06-28 US disclosed
EP-0757682-B1 BENZOFURAN DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION FUJISAWA PHARMACEUTICAL CO (JP) 2001-06-20 EP disclosed
US-5858995-A ADMINISTERING TO HUMANS AND ANIMALS IN THE TREATMENT OF DISEASES CAUSED BY ABNORMAL BONE METABOLISM FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-01-12 US disclosed
EP-0757682-A1 BENZOFURAN DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-02-12 EP disclosed
WO-1996034866-A1 IMIDAZO 1,2-A PYRIDINE AND IMIDAZO 1,2-A PYRIDEZINE DERIVATIVES AND THEIR USE AS BONE RESORPTION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-11-07 WO disclosed
WO-1995029907-A1 BENZOFURAN DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-11-09 WO disclosed